Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update by Seini Moimoi | May 16, 2022 | Uncategorized, Portfolio News
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH by Seini Moimoi | Jun 10, 2021 | Uncategorized
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency by Seini Moimoi | Jun 9, 2021 | Uncategorized
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China by Seini Moimoi | Dec 7, 2020 | Uncategorized
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib by Seini Moimoi | Aug 6, 2020 | Uncategorized
